Access to donidalorsen for people who completed a long-term study
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This program gives access to the study drug donidalorsen for people who have already been in a long-term study for hereditary angioedema. It is for those who finished the full 4 years of treatment and want to continue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed about 4 years (205 weeks) of treatment in the open-label extension study.
- If you could become pregnant (or your partner could), you must be willing to use reliable birth control or avoid sexual activity.
- You cannot be pregnant or planning to become pregnant.
- You must not have stopped the earlier study early because of a serious side effect related to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
This program provides an experimental treatment called deucrictibant for people with hereditary angioedema (HAE) who have attacks that are not controlled by other approved medicines. It aims to see if this treatment can safely and effectively stop HAE attacks when other options have failed.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study follows people who previously got the experimental drug NTLA-2002 in an Intellia trial. It checks long-term safety and health effects, even if you already stopped treatment.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This trial tests if sebetralstat can prevent swelling attacks before medical procedures in people with HAE types I or II. You take the medicine short-term before your procedure to see if it helps protect you from an attack.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.